A Phase 3, Open-label Study to Assess the Clinical Utility of Fluciclovine (18F) PET/CT in Patients With Prostate Cancer With Biochemical Recurrence After Radical Treatment
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Jul 2017
At a glance
- Drugs Fluciclovine 18F (Primary)
- Indications Prostate cancer
- Focus Diagnostic use; Registrational
- Acronyms FALCON
- Sponsors Blue Earth Diagnostics
- 10 Jun 2017 Biomarkers information updated
- 03 May 2017 Planned End Date changed from 1 Jan 2017 to 1 Dec 2017.
- 03 May 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.